Comparing two drug combinations after first-line liver cancer treatment
This trial is for people with liver cancer that cannot be removed by surgery. It tests whether adding a targeted therapy (lenvatinib) to the current combination of bevacizumab and an immunotherapy (PD-1 inhibitor) works better than continuing without lenvatinib, for those whose disease progressed after initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of hepatocellular carcinoma (the most common type of liver cancer) that cannot be removed by surgery.
- You are between 18 and 75 years old and received at least two cycles of a standard first-line treatment with bevacizumab plus sintilimab (both given as IV infusions every 3 weeks).
- Your cancer has been confirmed to have grown despite that first-line treatment, based on imaging scans.
- After that progression, you have received at least two cycles of further treatment with either bevacizumab plus sintilimab, lenvatinib, or a similar drug (regorafenib) combined with a PD-1 inhibitor.
- Your blood test results meet certain minimum levels for liver function, kidney function, and blood cell counts (for example, platelets and white blood cells).
- You do not have another active cancer or a serious health condition that would interfere with the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a more intensive treatment is better than switching to another therapy for people with advanced liver cancer (HCC) that got worse after a first treatment with bevacizumab and sintilimab. It aims to find a more effective option for patients who need a next step.
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
This trial tests a new drug combination (ZG005 plus bevacizumab) against a standard one (sintilimab plus bevacizumab) as the first treatment for advanced liver cancer that cannot be removed by surgery. The goal is to see if the new combination works better at shrinking tumors or delaying progression.
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
This trial tests whether combining a PD-L1 antibody (an immunotherapy) with bevacizumab (a drug that slows blood vessel growth to tumors) and a liver-directed chemotherapy infusion can help people with advanced liver cancer that has spread outside the liver. It is designed for patients who have not previously received these specific treatments.
Hear when a new Hepatocellulcar Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.